Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Biotech
Takeda culls cancer, gut and inflammation drugs in R&D rethink
Takeda has taken an ax to its pipeline, hacking off midphase and early-stage programs as part of a push to focus on its most promising prospects.
Nick Paul Taylor
May 9, 2024 5:13am
Kyverna overshoots raised IPO expectations with $319M offering
Feb 8, 2024 8:24am
Rallybio drops 45% of workforce to extend cash runway into 2026
Feb 6, 2024 9:45am
J&J's $6.5B drug hits goal in phase 3, teeing up approval talks
Feb 5, 2024 9:37am
Still under partial hold, Sanofi makes case for safety of MS med
Apr 28, 2023 11:16am
Harbour ships phase 3 data to take lead in autoimmune race
Mar 6, 2023 6:50am